Physician profile
Tejdeep Singh
NPI 1356317622
$440.90
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $18.19 · 2021: $52.51 · 2022: $45.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $83.32 | 2019 | |
| Amgen INC. | $69.80 | 2019 | |
| Novo Nordisk INC | $62.79 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $40.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.27 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $22.71 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.47 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.80 | 2022 | |
| Lilly USA, LLC | $13.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.66 | 2019 | |
| Abbvie INC. | $13.50 | 2022 | |
| Glaxosmithkline, LLC. | $13.26 | 2019 | |
| Pfizer INC. | $12.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejdeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.